Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.77%
$25.96
0% positive prob.
5-Day Prediction
-3.21%
$25.58
0% positive prob.
20-Day Prediction
-11.65%
$23.35
0% positive prob.
SEC 8-K filings with transcript text
Feb 24, 2026 · 100% conf.
1D
-1.77%
$25.96
5D
-3.21%
$25.58
20D
-11.65%
$23.35
elan-20260224FALSE000173910400017391042026-02-242026-02-24
Washington, D.C. 20549
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2026
Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)
001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)
46221
(Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (877) 352-6261
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 24, 2026, announcing the results of operations for the full year and fiscal quarter ended December 31, 2025, and guidance for the full year and first quarter of 2026, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
99.1Press Release issued by Elanco Animal Health Incorporated dated February 24, 2026
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:February 24, 2026/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer
Nov 5, 2025
elan-20251105FALSE000173910400017391042025-11-052025-11-05
Washington, D.C. 20549
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)
001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)
46221
(Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (877) 352-6261
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated November 5, 2025, announcing the results of operations for the fiscal quarter ended September 30, 2025, and guidance for the full year and fourth quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
99.1Press Release issued by Elanco Animal Health Incorporated dated November 5, 2025
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:November 5, 2025/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer
Aug 7, 2025
elan-20250807FALSE000173910400017391042025-08-072025-08-07
Washington, D.C. 20549
Form 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter)
001-38661 82-5497352 (State or other jurisdiction of(Commission File (I.R.S. Employer incorporation)Number) Identification No.)
46140
(Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (877) 352-6261
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, no par valueELANNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations or Financial Condition. Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 7, 2025, announcing the results of operations for the fiscal quarter ended June 30, 2025, and guidance for the full year and third quarter of 2025, for Elanco Animal Health Incorporated. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
99.1Press Release issued by Elanco Animal Health Incorporated dated August 7, 2025
104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:August 7, 2025/s/ Robert M. VanHimbergen Robert M. VanHimbergen Executive Vice President and Chief Financial Officer
This page provides Elanco Animal Health Incorporated (ELAN) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ELAN's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.